MEDTRONIC RESOLUTE ONYX

Description

INDICATION

The Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length 35 mm in native coronary arteries with reference vessel diameters of 2.0 mm to 5.0 mm. In addition, the Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System is indicated for treating de novo chronic total occlusions.

The Resolute Onyx stent is indicated for the treatment of the following patient and lesion subsets:



Diabetes mellitus

Multivessel disease

Acute coronary syndrome ACS

Acute myocardial infarction AMI

Unstable angina UA

Bifurcation lesions

In-stent restenosis ISR

Chronic total occlusions CTO

Total occlusions TO



The Resolute Onyx stent is intended to improve coronary luminal diameters of either single or multiple vessels as an adjunct to coronary interventions and to reduce restenosis. The stent is intended as a permanently implanted device.



KEY CLINICAL MESSAGES



Comprehensive, unique Global RESOLUTE clinical program, with more than 7500 Resolute™ DES patients are enrolled

Safety and efficacy sustained at 5 years

No increased risk of ST in Resolute™ DES patients interrupting DAPT beyond 1 month

Strong performance in complex casesLow event rates in patients with diabetes, despite higher comorbidities

Proven long-term outcomes in complex bifurcation lesions